Branded Prescription Drug Fee (US Internal Revenue Service Regulation) (IRS) (2018 Edition)

Branded Prescription Drug Fee (US Internal Revenue Service Regulation) (IRS) (2018 Edition) The Law Library presents the complete text of the Branded Prescription Drug Fee (US Internal Revenue Service Regulation) (IRS) (2018 Edition). Updated as of May 29, 2018 This document contains temporary regulations that provide guidance on the annual fee imposed on covered entities engaged in the business of manufacturing or importing branded prescription drugs. This fee was enacted by section 9008 of the Patient Protection and Affordable Care Act, as amended by section 1404 of the Health Care and Education Reconciliation Act of 2010. The regulations affect persons engaged in the business of manufacturing or importing certain branded prescription drugs. The text of the temporary regulations also serves as the text of the proposed regulations set forth in the notice of proposed rulemaking on this subject in the Proposed Rules section of this issue of the Federal Register. This book contains: - The complete text of the Branded Prescription Drug Fee (US Internal Revenue Service Regulation) (IRS) (2018 Edition) - A table of contents with the page number of each section